VJOncology is committed to improving our service to you

ESMO 2018 | Ovarian news from ESMO 2018: SOLO-1 results for olaparib

VJOncology is committed to improving our service to you

Kathleen Moore

Ovarian cancer research is moving forwards, as displayed at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Kathleen Moore, MD, MS, of the Stephenson Cancer Center, Oklahoma City, OK, gave an update on the SOLO-1 trial (NCT01844986) of olaparib maintenance monotherapy for BRCA-mutated ovarian cancer after first-line platinum-based chemotherapy.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter